AIA Group Ltd Acquires 2,493 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• AIA Group Ltd increased its holdings in Regeneron Pharmaceuticals by 18.3% during the 1st quarter, owning 16,093 shares valued at approximately $10.2 million.
• Regeneron reported earnings of $12.89 per share for the last quarter, significantly exceeding analysts' expectations of $8.43, with revenues reaching $3.68 billion.
• The company announced a quarterly dividend of $0.88 per share, providing investors with an annualized dividend yield of 0.6%.

AIA Group Ltd increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 18.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,093 shares of the biopharmaceutical company's stock after purchasing an additional 2,493 shares during the quarter. AIA Group Ltd's holdings in Regeneron Pharmaceuticals were worth $10,207,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Independent Advisor Alliance lifted its holdings in Regeneron Pharmaceuticals by 98.7% in the first quarter. Independent Advisor Alliance now owns 950 shares of the biopharmaceutical company's stock valued at $603,000 after acquiring an additional 472 shares during the period. Cove Private Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 4.5% in the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company's stock valued at $292,000 after acquiring an additional 20 shares during the period. SouthState Corp lifted its holdings in Regeneron Pharmaceuticals by 550.0% in the first quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 44 shares during the period. Nuveen LLC bought a new position in Regeneron Pharmaceuticals in the first quarter valued at about $343,764,000. Finally, Cooper Financial Group lifted its holdings in Regeneron Pharmaceuticals by 42.2% in the first quarter. Cooper Financial Group now owns 758 shares of the biopharmaceutical company's stock valued at $480,000 after acquiring an additional 225 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 0.9%

Shares of NASDAQ:REGN traded up $5.00 during trading on Wednesday, hitting $561.55. The company had a trading volume of 1,095,985 shares, compared to its average volume of 986,192. The stock has a market cap of $59.52 billion, a price-to-earnings ratio of 14.15, a price-to-earnings-growth ratio of 1.88 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a fifty day simple moving average of $540.81 and a two-hundred day simple moving average of $597.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3,675,600 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The company's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period last year, the company earned $11.56 EPS. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on REGN shares. Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research report on Monday, August 4th. Guggenheim upped their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. Finally, Robert W. Baird reduced their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $835.74.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.